Hydroxyurea-Induced Pneumopathy in a Patient With Myeloproliferative Syndrome

1Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Hydroxyurea (HU) is a drug frequently used in the treatment of chronic myeloproliferative neoplasms. The most common side effects of this drug are pancytopenia, digestive and skin disorders. Respiratory complications are rare and there are less than 20 cases described, only 5 of which underwent an anatomopathological study. We present the case of a patient with chronic myeloproliferative neoplasm who developed interstitial pneumonitis probably due to HU according to histological study.

Cite

CITATION STYLE

APA

Galván, O. P., Moltó, H. P., Fabià-Mayans, A., Xicoy, B., Mate, J. L., & Martí, P. R. (2018). Hydroxyurea-Induced Pneumopathy in a Patient With Myeloproliferative Syndrome. Clinical Medicine Insights: Case Reports, 11. https://doi.org/10.1177/1179547618770688

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free